Cure & Immunotherapies
This Think Tank develops and tests targeted immunotherapies and therapeutic vaccines to decrease viral reservoirs and find cures for HIV and hepatitis B, and vaccines for syphilis, HPV, and hepatitis C.
-
CTN 158: The CpG ODN 7909 as an Adjuvant and Immune Modulator
Phase I Safety and Immunogenicity Study of CpG ODN 7909 as an Immune Modulator and Adjuvant to Engerix®-B Vaccine in Haart-Treated, HIV-Positive Patients: Trial results
-
CTN 149: Two PIs versus Efavirenz, with Two NRTIs
Open-Label, Randomized, Multicenter Study to Evaluate Fortovase® (Saquinavir SGC) QD, Norvir® (Ritonavir) QD plus Two NRTIs Vs. SustivaTM (Efavirenz) QD plus Two NRTIs in HIV-Infected Patients: Trial results
-
CTNPT 032: The Camu Camu Pilot Study
Camu Camu effects on circulating LPS and systemic immune activation in ART-treated participants
-
-
-
CTN 239: Phase II study of AGS-004 an immunotherapeutic agent in combination with ART followed by ART interruption
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
-
CTN 229: Effect of AGS-004 immunotherapeutic agent in HIV-positive people on HAART
A pilot study (Phase I/II) testing the immunologic activity and safety of AGS-004, an autologous HIV immunotherapeutic, in HIV-infected adults on HAART: Trial results
-
CTN 256: Phase IIB study of efficacy and safety of AGS-004
A randomized, double blind, phase IIB study testing the efficacy and safety of AGS-004 on host control of HIV replication during analytical treatment interruption: Trial results
-
CTNPT 006: The Niaspan® study
Role of extended-released niacin on immune activation in HIV-infected patients treated with antiretroviral therapy: a proof-of-concept study